Literature DB >> 32891227

Recent Actions by the US Food and Drug Administration: Reducing the Risk of Infection from Reprocessed Duodenoscopes.

Shanil P Haugen1, Ann Ferriter2, Jian Connell2, Lauren J Min2, Hanniebey D Wiyor2, Stephanie Cole2.   

Abstract

In addition to technological advancements, engagement and collaboration among the wider community of stakeholders will be beneficial toward reducing the risk of infection from reprocessed duodenoscopes. Such a community can raise awareness of the importance of duodenoscope cleaning, work to improve reprocessing training, identify the most pressing unanswered questions that merit further research, and develop tools that can be used by health care facilities to improve the quality of reprocessing at their sites. The Food and Drug Administration looks forward to working with the community to further reduce the risk of infections from reprocessed duodenoscopes. Published by Elsevier Inc.

Entities:  

Keywords:  Duodenoscopes; FDA; Infection; Reprocessing

Mesh:

Year:  2020        PMID: 32891227     DOI: 10.1016/j.giec.2020.06.010

Source DB:  PubMed          Journal:  Gastrointest Endosc Clin N Am        ISSN: 1052-5157


  3 in total

1.  Rate and impact of duodenoscope contamination: A systematic review and meta-analysis.

Authors:  Sara Larsen; Rasmus Vinther Russell; Lotte Klinten Ockert; Stephen Spanos; Helena Strømstad Travis; Lars Holger Ehlers; Anders Mærkedahl
Journal:  EClinicalMedicine       Date:  2020-07-15

2.  Single-use duodenoscopes for the prevention of endoscopic retrograde cholangiopancreatography -related cross-infection - from bench studies to clinical evidence.

Authors:  Andrea Lisotti; Pietro Fusaroli; Bertrand Napoleon; Anna Cominardi; Rocco Maurizio Zagari
Journal:  World J Methodol       Date:  2022-05-20

3.  Investigation of possible transmission of a susceptible microorganism through a contaminated duodenoscope; a case report.

Authors:  Marco J Bruno; Margreet C Vos; Judith A Kwakman; Arjan W Rauwers; Corné H W Klaassen
Journal:  Antimicrob Resist Infect Control       Date:  2021-08-28       Impact factor: 4.887

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.